Clinical Laserthermia Systems sits in the early ramp phase of its cycle. Third-quarter revenue increased 80 percent year on year to SEK 5.0 million while gross margin remained above 60 percent, but January–September revenue stayed 16 percent below the prior year after a weak start during discussions with the neurosurgery partner. The company continues to expect double-digit revenue growth for full-year 2026 compared with 2025.
Site activation and the buildup of procedure volumes require time, so revenue can vary between quarters.
Clinical Laserthermia Systems' growth trajectory depends on turning steady Prism deliveries into activated sites and recurring procedure volume, while published clinical evidence and partnerships without committed volumes serve as early indicators rather than assured revenue. Third-quarter revenue grew 80 percent from the prior-year quarter, reaching SEK 5.0 million, with gross margin above 60 percent. The company expects double-digit revenue growth for full-year 2026 relative to 2025, with revenue contingent on delivery timing, system placements, and how quickly procedure volumes ramp up.
Revenue for January through September remained 16 percent below the prior year, a weak start amid talks with the neurosurgery partner. Clinical Laserthermia Systems entered a strategic partnership agreement with advanced fiber tools GmbH, pairing its non-cooled laser technology with AFT's fiber-optic engineering and manufacturing expertise. The agreement sets up a non-exclusive arrangement for assessing opportunities, with individual projects settled separately, and carries no immediate financial commitments and no guaranteed commercial volumes.
Clinical Laserthermia Systems is a partner in a five-year Dartmouth Health program funded by the National Cancer Institute with USD 2.98 million to advance MR-guided LITT for spinal metastases. A phase 1 study of 14 patients at Skåne University Hospital using the Prism System shows MR-guided LITT safety and feasibility in glioblastoma and grade 4 astrocytoma. An October AES/CNS epilepsy guideline strengthens the framework for LITT in defined drug-resistant epilepsy groups without endorsing a commercial system.
The category shift helps Clinical Laserthermia on modality mix but not yet on clinical acceptance: laser ablation rose from 14.6% of focal therapy procedures in 2010 to 45.8% in 2023 while cryotherapy fell from 79.8% to 19.1%, yet AUA/ASTRO guidelines counsel that whole-gland or focal ablation remains investigational for patients with low- and intermediate-risk prostate cancer and that high-quality evidence comparing focal therapy against standard-of-care treatments is lacking.
Grand View Research put the global prostatic ablation devices market at USD 2.2 billion in 2025 and forecasts it growing from USD 2.5 billion in 2026 to USD 6.3 billion by 2033 at 14.0% compounded annually, with North America accounting for 46.4% of market revenue in 2025.
A national analysis found that 51% of focal therapy procedures for prostate cancer involved low-, high-, or very-high-risk patients outside current guideline-supported settings, while focal therapy overall accounted for only 1.3% of 1,179,384 men with nonmetastatic prostate cancer diagnosed from 2010 through 2023.
Clinical Laserthermia Systems' revenue recovery is fragile: revenue for January–September remained 16 percent below last year after a weak start during discussions with its neurosurgery partner. The 2026 outlook assumes the Company completes planned financing activities, which would provide financial flexibility needed to carry out its accelerated commercialization strategy and meet known financial commitments. The issued TO 9 B warrants offer a potential additional capital source in March 2027, with proceeds contingent on the extent to which holders exercise them.
The time needed to activate sites and grow procedure volumes means revenue can vary between quarters. Clinical Laserthermia Systems' immediate focus covers supporting commercial execution in the U.S and advancing the regulatory work needed for European market access.
Clinical Laserthermia Systems completed a rights issue of units that was subscribed to approximately 78.5 percent including subscription and guarantee undertakings, raising approximately SEK 31 million before transaction-related costs.